Similar articles

• Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.

  Bismuth H. Bismuth H. Transplant Proc. 1995 Feb;27(1):45-9. Transplant Proc. 1995. PMID: 7533415 Clinical Trial. No abstract available.
• Neurotoxicity of FK 506 in liver transplant recipients.

  Frank B, Perdrizet GA, White HM, Marsh JW, Lemann W, Woodle ES. Frank B, et al. Transplant Proc. 1993 Apr;25(2):1887-8. Transplant Proc. 1993. PMID: 7682355 Clinical Trial. No abstract available.
• Two-year experience with FK 506 in pediatric patients.

  Tzakis AG, Reyes J, Todo S, Nour B, Shapiro R, Jordan M, McCauley J, Armitage J, Fung JJ, Starzl TE. Tzakis AG, et al. Transplant Proc. 1993 Feb;25(1 Pt 1):619-21. Transplant Proc. 1993. PMID: 7679822 Free PMC article. Clinical Trial. No abstract available.
• Clinical use of FK 506 in liver transplantation.

  Klintmalm GB. Klintmalm GB. Transplant Proc. 1996 Apr;28(2):974-6. Transplant Proc. 1996. PMID: 8623484 Review.
• [Controversies about the use of calcineurin inhibitors in pediatric patients].

  Dello Strologo L. Dello Strologo L. G Ital Nefrol. 2008 May-Jun;25(3):317-24. G Ital Nefrol. 2008. PMID: 18473303 Review. Italian.